27 matches for your search in the start-up spotlight
rss
Noema Pharma is a clinical-stage biotech company advancing a portfolio of transformative therapeutics utilizing first-in-disease approaches targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating pain in ...
AQEMIA is a next-gen pharmatech company generating one of the world's fastest-growing drug discovery pipeline. Our mission is to design fast innovative drug candidates for dozens of critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms fueling a ...
Pentixapharm is a radiopharmaceutical development company founded in 2019, with its headquarters in Würzburg, Germany. Its clinical pipeline encompasses PentixaTher, an Yttrium-90 based therapeutic against CNS lymphoma, and PentixaFor, a Gallium-68 based companion diagnostic. Clinical studies for ...
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The ...
Since its launch in 2019, the Frankfurt-based company has been committed to supporting pharma companies with fast, flexible, and reliable supply chain compliance assessments. With a global network of over 200 local expert auditors, 1,000+ pharma clients, and the world’s largest database of ...
EG 427 has developed a unique, non-replicative Herpes Simplex Virus type 1 (nrHSV-1) based vector platform. It delivers, with pinpoint precision, highly selective, durable expression of disease modifying transgenes. We take advantage of it to design new treatments of peripheral nervous system ...
We are developing the first pro-drug platform on RNA level, targeting oncological, viral and genetic diseases. It is our mission to open a new chapter in treating diseases and to deliver so called selectively expressed RNAs (seRNAs) to patients. We have an ambitious pipeline that targets ...
QLi5 was founded in 2019 as a joint venture of Qurient Co. Ltd, Korea, Max Planck Society (MPG), Germany, Lead Discovery Center (LDC), Germany, Nobel laureate Prof. Robert Huber, emeritus director of the Max Planck Institute for Biochemistry, Germany. The company has established a proprietary ...
KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, next-generation oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform that can generate potent novel oncolytic vaccinia viruses with modifications to maximize ...
G.ST Antivirals is an Austrian start-up founded in 2019 as a spin-off from the Medical University of Vienna. The young company has its roots in extensive research on the inhibition of rhinovirus infections. Based on this, G.ST Antivirals developed a patented, innovative drug against colds. Since ...
